astrazeneca cardiovascular hamish cameron vice president & head of ta cancer other and unknown causes infectious parasitic diseases chronic obstructive lung injury poisoning maternal perinatal death the burden disease making most our marketed products h atacand zestril zestoretic seloken zok toprol xl tenormin inderal plendil logimax pramace unimax imdur sular canef niften sorbitrat suscard bamycor xylocard tonocard quinidine durules prokainamid dirytmin angiotensinogen angiotensin i ii sodium fluid retention vaso constriction sympathetic activation cell growth at 1 receptor renin ace non pathways kinins inactive fragments blockade system a rational approach to antihypertensive treatment number in usa evidence based prevention end organ damage documented hypertension chf ami diabetic complications nephropathy retinopathy paediatric documentation extend exclusivity mid 2002 acei diuretic combination key studies reporting hope atlas stop 2 source scott levine pdda ims health 1999
